Equities

Utah Medical Products Inc

Utah Medical Products Inc

Actions
  • Price (EUR)62.50
  • Today's Change1.00 / 1.63%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Utah Medical Products Inc had little change in net income (from 16.47m to 16.64m) despite revenues that fell -3.93% from 52.28m to 50.22m.
Gross margin58.99%
Net profit margin33.56%
Operating margin32.71%
Return on assets12.00%
Return on equity12.72%
Return on investment12.43%
More ▼

Cash flow in USDView more

In 2023, Utah Medical Products Inc increased its cash reserves by 23.74%, or 17.82m. The company earned 22.28m from its operations for a Cash Flow Margin of 44.36%. In addition the company used 639.00k on investing activities and also paid 4.17m in financing cash flows.
Cash flow per share5.49
Price/Cash flow per share12.05
Book value per share35.45
Tangible book value per share30.45
More ▼

Balance sheet in USDView more

Utah Medical Products Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 92.87m.
Current ratio25.98
Quick ratio23.68
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)1.21%
Div growth rate (5 year)1.86%
Payout ratio (TTM)27.46%
EPS growth(5 years)2.27
EPS (TTM) vs
TTM 1 year ago
-8.76
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.